Company news

InMed Pharmaceuticals Inc. news in 2023

InMed Pharmaceuticals Inc.'s news releases, calls and decks from 2023, newest first.

View company

InMed Announces Results of 2023 Annual General Meeting

December 18, 2023

InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration

November 28, 2023

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

November 13, 2023

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

November 1, 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

October 25, 2023

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

October 23, 2023

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

October 23, 2023

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

September 28, 2023

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

June 21, 2023

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

May 14, 2023

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

March 27, 2023

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

March 12, 2023

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 16, 2023

InMed Submits Form 12b-25

February 8, 2023

InMed Provides Business Update and Milestones for 2023

January 9, 2023

Decks in 2023